Genmab — Juli 2013
-
det kunne nogle gode tal bremse idag
-
Oncology and emesis
Q2 2013 (£233 million; up 17%)
Three new products, Votrient, up 97% to £79 million, Promacta, up 53% to £45 million, and Arzerra, up 20%
to £17 million, all continued to drive growth. Tykerb/Tyverb sales fell 12% to £53 million and both Hycamtin
in Europe and Argatroban in the US continued to be adversely affected by generic competition.
In the US, Votrient sales grew 70% to £36 million and sales of Promacta grew 38% to £19 million, reflecting
the benefit of a new indica -
H1 2013 (£454 million; up 20%)
Votrient sales more than doubled to £150 million, Promacta sales grew 51% to £85 million and Arzerra sales
grew 41% to £38 million. Tykerb/Tyverb sales fell 13% to £105 million and both Hycamtin in Europe and
Argatroban in the US continued to be adversely affected by generic competition. -
Jeg er målløs - GEN indleverer IND på et helt nyt og meget lovende område. Over den efterfølgende uge taber selskabet 10% i værdi uden egentlige nyheder....
-
Hvad er det, vi overser?
-
er det bare handel og vandel? Ikke noget med den fundamentale værdi...
-
Der er simpelthen ingen, der gider købe den!
-
den er steget ret meget de sidste 2 år. Vi skal jo se en reaktion på et tidspunkt
-
hold nu kæft en lorteuge - hvis en IND kan medføre sådan et fald i et positivt marked, hvad sker der så ikke ved en godkendelse i first line cll!?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind